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Abstract The cDNA encoding murine procathepsin E was 
isolated and sequenced and recombinant enzyme was produced in 
Escherichia coli. The activity of the purified recombinant mouse 
cathepsin E was characterised quantitatively using two synthetic 
peptide substrates and naturally occurring inhibitors. The 
majority of the recombinant enzyme was present as a homodimer 
(Mr ~ 8 0 ) in which the two monomers were linked by an 
intermolecular disulfide bond. By analogy to previous studies 
with human cathepsin E, this is most likely a consequence of the 
presence of a unique cysteine residue near the N-terminus of the 
mature proteinase. The availability of (i) recombinant murine 
enzyme in reasonable quantities and (ii) a full-length cDNA now 
enables structural investigations and attempts to generate 
'knock-out' mice deficient in this important aspartic proteinase 
to be undertaken. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Of the five aspartic proteinases currently documented to be 
produced in the human body, three (pepsin, gastricsin and 
renin) have well-defined physiological roles and the fourth, 
cathepsin D, is found ubiquitously in the lysosomes of most 
cells [1]. The fifth enzyme, cathepsin E, is readily distinguished 
from the others by its molecular architecture [2], its cytomor-
phological compartmentat ion [3] and its limited tissue and 
cellular distribution. The enzyme has been postulated to 
have roles in prohormone [4] and antigen processing [5] and 
in neurodegeneration, ischemia and ageing [6-8]. Definitive 
evidence in support of these putative roles has, however, re-
mained elusive. 
It was thus considered that one approach to establishing the 
physiological role(s) of cathepsin E unequivocally would be 
the generation of 'knock-out ' mice lacking a functional pro-
cathepsin E gene. As a prelude to this extensive research pro-
gramme, it was necessary to derive a c D N A encoding murine 
procathepsin E and to characterise the mouse enzyme. 
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Abbreviations: RT-PCR, reverse transcriptase polymerase chain 
reaction; RACE, rapid amplification of cDNA ends 
2. Materials and methods 
2.1. Isolation of the cDNA sequence encoding murine procathepsin E 
Specific amplification of the procathepsin E cDNA was achieved by 
a combination of RT-PCR and 5'- and 3'-RACE. The mRNA was 
isolated and purified from the spleen of BALB/c mice using the 
mRNA purification kit (Pharmacia Biotech Ltd., Milton Keynes, 
UK). First-strand cDNA synthesis was achieved by using reverse tran-
scriptase with either random hexamers or a modified oligo(dT)i7 (see 
below). All oligonucleotides were purchased from Genosys Biotech-
nologies Inc., Cambridge, UK. 
The initial PCR product was amplified from random-primed cDNA 
using degenerate primers (forward primer 1 =5'-CTG CTG ITG 
CTC CTG GAI CTG G-3' and reverse primer 2 = 5 '-GGGAAC 
TGC IGG GGC CAI ICC CAC-3' where I = inosine). The resultant 
(1167 bp) product A encompassed almost the full-length procathepsin 
E gene. 
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The 3'-RACE product (designated B) was amplified by utilising the 
strategy described previously [9], in which the first-strand cDNA was 
synthesised by using reverse transcriptase and the modified 
oligo(dT)i7 primer (CGG AGA TCT CCA ATG TGA TGG GAA 
TTC (T)i7). Specific PCR reactions were performed using the gene-
specific forward primer 3 (5'-AT GGA ATG CAG TTC TGC GGC-
3') which was designed against authentic murine procathepsin E 
cDNA sequence and the reverse primer 4 corresponding to the 
oligo(dT)i7 primer used in the first-strand synthesis but devoid of 
the oligo(dT),7 tail, i.e. (5'-CGG AGA TCT CCA ATG TGA 
TGG GAA TTC-3'). The resultant 760 bp product B (see above) 
contained a 152 bp overlap with product A and included the 3'-end 
flanking region and the poly-A sequence. 
The 437 bp 5'-RACE product (designated C) was amplified accord-
ing to standard procedures [10,11] utilising reverse transcriptase 
and the procathepsin E gene-specific reverse primer 5 (5'-
GAT TCC TGT CAG GCT CCC-3'). Homopolymeric tailing of 
the cDNA was achieved using terminal transferase and dCTP. PCR 
reactions were performed using a nested reverse primer 6 (5'-
CGA TGG ATG GAA TAC TGG G-3') and a forward oligo(dG)i5 
primer. The resultant product C overlapped product A by 351 bp and 
extended the sequence information to include an additional 47 bp in 
the 5'-flanking region prior to the start of translation. Despite many 
attempts, this 5'-RACE product was obtained on only one occasion. 
Consequently, to confirm the cDNA sequence of this 5-' region, a new 
primer was designed (forward primer 7 = 5'-GI Gil AAG CTG CII 
IIC IIA C-3') and used in conjunction with the nested reverse primer 
6 to enable the amplification of a 401 bp PCR product (designated D). 
All PCR amplifications were performed using 10-20 ng of reverse 
transcribed mRNA, 1 U of Amplitaq DNA polymerase (Perkin Elmer 
Corp., Roche Molecular Systems Inc., New Jersey), 1 mM MgCl·;, 0.5 
mM of each primer and 200 mM dNTPs in a final volume of 50 ml. 
An initial denaturation step of 94°C for 3 min was typically followed 
by 40 cycles of 94°C for 1 min, 60°C for 1 min and 72°C for 1.5 min, 
after which a final elongation step of 72°C for 5 min was performed 
using a Perkin Elmer Cetus DNA thermal cycler 480 programmable 
thermoblock. Each PCR product was amplified on a minimum of 
three separate occasions and each independent product was cloned 
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aagggagatcggagcagagtgagagagaagctaccccttggaccaca ATG AAG CCC CTC CTT GTG CTG CTG CTG CTG CTG CTC CTG GAT CTG GCT CAG GCC 101 
IP 10P 20P 30P 
Q G A L H R V P L R R H Q S L R K K L R A Q G Q L S E F W R 30P 
CAA GGT GCT CTG CAC AGA GTG CCC CTC AGA AGA CAT CAG TCC CTT CGG AAG AAA CTA CGG GCC CAA GGA CAG CTC TCA GAA TTC TGG AGG 191 
31P -I 39P J-l V I 10 20 
S H N L D M T R L S E S C N V Y S S V N E P L I N Y L D M E 21 
TCT CAT AAC TTG GAC ATG ACC CGA CTC AGC GAG TCC TGT AAT GTG TAT TCG AGT GTC AAT GAA CCC CTC ATC AAC TAC CTG GAT ATG GAA 281 
30 ♦ T 50 
Y F G T I S I G T P P Q N F T V I F D T G S S N L W V P S I 51 
TAC TTT GGC ACC ATC TCC ATC GGC ACC CCG CCG CAG AAC TTC ACT GTC ATC TTT GAC ACC GGT TCA TCC AAC CTC TGG GTC CCT TCT ATC 3 71 
60 70 80 
V Y C T S P A C K A H P V F H P S Q S D T Y T E V G N H F S 81 
GTG TAC TGC ACC AGC CCA GCA TGC AAG GCA CAC CCA GTA TTC CAT CCA TCG CAG TCC GAC ACÁ TAC ACG GAG GTA GGG AAT CAT TTC TCC 461 
90 100 110 
Q Y G T G S L T G I I G A D Q V S V E G L T V D G Q Q F G B 111 
CAG TAT GGT ACC GGG AGC CTG ACA GGA ATC ATT GGA GCT GAT CAA GTC TCT GTG GAA GGG TTG ACT GTG GAT GGC CAG CAG TTT GGA GAA 551 
120 130 140 
S V K E P G Q T F V N A E F D G I L G L G Y P S L A A G G V 141 
AGT GTC AAG GAG CCA GGC CAG ACC TTT GTG AAT GCA GAG TTT GAT GGG ATT CTG GGT CTG GGA TAC CCC TCA TTG GCT GCT GGA GGA GTG 641 
150 160 170 
T P V F D N M M A Q N L V A L P M F S V Y L S S D P Q G G S 171 
ACC CCA GTG TTT GAC AAC ATG ATG GCC CAG AAC CTT GTG GCT CTG CCT ATG TTT TCT GTC TAC TTG AGC AGT GAC CCT CAA GGT GGC TCA 731 
180 190 200 
G S E L T F G G Y D P S H F S G S L N W I P V T K Q A Y W Q 201 
GGC AGT GAG CTG ACT TTC GGA GGC TAT GAC CCC TCT CAT TTC TCT GGG AGC CTC AAC TGG ATT CCA GTC ACC AAG CAA GCC TAT TGG CAG 821 
210 220 ▼ 230 
I A L D G I Q V G D T V M F C S E G C Q A I V D T G T S L I 231 
ATT GCC TTG GAT GGA ATC CAG GTG GGA GAC ACT GTG ATG TTC TGC TCC GAA GGC TGT CAG GCC ATA GTG GAC ACA GGG ACC TCT CTC ATC 911 
240 250 260 
T G P P D K I K H L Q E A I G A T P I D G E Y A V D C A T L 261 
ACT GGC CCC CCC GAC AAG ATC AAA CAT CTT CAA GAG GCC ATT GGG GCC ACA CCC ATT GAT GGA GAA TAT GCA GTG GAT TGT GCC ACT CTC 1001 
♦ 270 ♦ 280 290 
D T M P N V T F L I N E V S Y T L N P T D Y I L P D L V D G 291 
GAC ACG ATG CCA AAC GTT ACC TTC CTC ATC AAC GAG GTT TCA TAT ACC CTC AAC CCA ACT GAC TAC ATC CTG CCG GAC TTG GTG GAT GGA 1091 
300 310 320 
M Q F C G S G F Q G L D I P P P A G P L W I L G D V F I R Q 321 
ATG CAG TTC TGC GGC AGT GGC TTT CAA GGA CTT GAC ATT CCA CCT CCA GCT GGG CCC CTC TGG ATC CTG GGG GAT GTC TTC ATC CGA CAG 1181 
330 340 
F Y S V F D R G N N Q V G L A P A V P * 340 
TTC TAC TCA GTC TTT GAC CGT GGA AAT AAC CAA GTG GGA TTG GCC CCC GCA GTT CCC TAA agagggatgtatgcctacatatggatgcctgatacccat 1280 
ttaacctgttagatacctttgtaactatcaaagccgtcatttcccatggggtgtagccaccccagagtattcagaccaatcaaagcataagagtgcaccccactcactgcaaacacaca 13 99 
cacacacacaccacctctaccatcaccacgatggaagaagttctgtctatagtcttcactgcttattgttgactttctattatggaaatctctaaacatgtacacagtagacgtgatgg 1518 
caagataaatacccacacacctctgcctcaggtcacaacccatccatgtgtggaccagactctctatcttccatccctctggttccacgcctctagatttggaagcagattctaagcac 163 7 
caggtcattttatctaatgtctaacatccttacaaatcagaatttaaatgcctcaccctctcataaatgtggatctgttttttacagttggtttatttgtatcaggattaaaaccagat 1756 
ccataactggacaaaaaaacccataactgatttgattttaaatatc(a)n 1802 
Fig. 1. The nucleotide and deduced amino acid sequence of the cDNA encoding murine procathepsin E. The residues in the putative signal 
peptide (numbers —18 to —1) are shown in italics. The Gin residue (indicated by IP) is the putative first amino acid of the pro-part. Residues 
1-340 represent the sequence of mature cathepsin E. The positions of the two active-site aspartic acid residues, the three potential N-linked gly-
cosylation sites and the Cys residue involved in the formation of the interchain disulfide bridge are indicated with τ , ♦ and v, respectively. 
The vertical arrows show the cleavage sites where the recombinant precursor undergoes auto-activation. 
using either the Promega pGEM-T PCR product cloning system 
(Promega Ltd., Southampton, UK) or the Pharmacia Sureclone lega-
tion Kit. Elucidation of the nucleotide sequences was achieved by 
dideoxy sequencing of both DNA strands using the Thermo Seque-
nase Kit (Amersham International, Amersham, UK) with primers 
labelled with fluorescent dyes and a Hybaid Licor Automated DNA 
Sequencer. 
2.2. Expression of procathepsin E in E. coli 
To facilitate the expression of recombinant murine procathepsin E 
in Escherichia coli, the DNA sequence encoding the propart and ma-
ture enzyme regions was amplified by PCR using the forward primer 
8 = 5'-G GAA TTC CAT ATG CAA GGT GCT CTG CAC AGA-
3' and the reverse primer 9 = 5'-CCC AGA TCT TTA GGG 
AAC TGC GGG GGG-3'. These primers contain Ndel and Bgäl 
restriction sites, respectively, to facilitate subsequent subcloning into 
the T7-RNA polymerase expression vector pETlób (AMS Biotech 
Ltd., Witney, Oxon, UK). DNA amplification was performed using 
100 ng of cDNA encoding murine procathepsin E, 1 U of Vent po-
lymerase (New England Biolabs, Beverly, MA), 2 mM MgS04, 
0.5 mM of each primer and 200 mM dNTPs in a final volume of 
50 ml. An initial denaturation step of 94°C for 3 min was followed 
by 10 cycles of 94°C for 1 min, 63°C for 1 min and 72°C for 1 min, 
after which a final elongation step of 72°C for 5 min was performed. 
The resultant 1162 bp product was cloned into pUC18 using the 
Sureclone Ligation Kit and, after authentication of the nucleotide 
sequence, the fragment was excised and subcloned into the Ndel/Bam-
HI sites of pET16b. Expression was carried out in E. coli BL21(DE3) 
pLysS as described previously [12,13]. 
The analysis of recombinant protein samples by SDS-PAGE and 
Western blotting, enzyme purification, N-terminal sequence analysis 
and determination of kinetic parameters for chromogenic substrate 
hydrolysis and inhibitor binding were carried out as described previ-
ously [13,14]. 
3. Results and discussion 
3.1. Analysis of DNA sequence encoding murine procathepsin E 
The nucleotide sequence of the cDNA-encoding murine 
procathepsin E (see Fig. 1) was determined by analysing 
both strands of the amplified DNA products generated as 
described in Section 2. It has been deposited in the EMBL, 
Genbank and DDBJ databases under the accession number 
X97399. The sequence consisted of 47 bp of 5'-untranslated 
region, a 1194 bp open-reading frame and 561 bp of 3'-flank-
ing region prior to the poly(A) tail. The open-reading frame 
predicts a 397-amino acid polypeptide (calculated Mt 
~42937) consisting of three regions; a signal peptide (18 
residues), a propart region of 39 residues and the mature 
enzyme (340 residues). The hallmark which distinguishes ca-
thepsin E from all other aspartic proteinases was readily evi-
dent in the murine sequence. This is the unique Cys4 residue 
(Fig. 1) which forms an intermolecular disulfide bond result-
ing in cathepsin E existing as a homodimer of ~ 8 0 kDa [15]. 
The coding sequence of murine procathepsin E and the 
deduced amino acid sequence were compared to those known 
for procathepsin E from other species. The identities (cDNA 
and amino acid, respectively) were 82% and 79% with human 
[16], 81% and 79% with guinea pig [17], 80% and 79% 
with rabbit [18] and 93% and 91% with rat [19] procathepsin 
E. 
The alignment is shown in Fig. 2. From this, a number of 
distinguishing features are apparent. 
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-18 -10 IP 10P 20P 30P +1 V 10 20 
Mouse MKPLLVLLLLLLL-DLAQAQGALHRVPLRRHQSLRKKLRAQGQLSEFWRSHNLDMTRLSESCNVYSSVNEPLINYLDMEY 
Rat F L V D IEF DKGI 
Rabbit T--P L G T D QP KA KV VQYT T TMEQ A 
Human T -- V LE GE S P K RS K IQFT SMDQ AK 
G.pig TF-- V L E G P S R E T L K Q N DQ STIQ A 
30 ♦ ▼ 50 60 70 80 90 100 
Mouse FGTISIGTPPQNFTVIFDTGSSNLWVPSVYCTSPACKAHPVFHPSQSDTYTEVGNHFSIQYGTGSLTGIIGADQVSVEGL 
Rat V S S S M 
Rabbit S V Q M Q R N S T P A Q 
Human S T SR Q S SQP QS S 
G.pig S QT L S R S 
110 120 130 140 150 160 170 180 
Mouse TVDGQQFGESVKEPGQTFVNAEFDGILGLGYPSLAAGGVTPVFDNMMAQNLVALPMFSVYLSSDPQGGSGSELTFGGYDP 
Rat E V 
R a b b i t V S M N E S 
Human V T D V D M N E A I H 
G . p i g V Q K H M N -
190 200 210 220 T 230 240 250 260 
M o u s e SHFSGSLNWIPVTKQAYWQIALDGIQVGDTVMFCSEGCQAIVDTGTSLITGPPDKIKHLQEAIGATPIDGEYAVDCATLD 
R a t G K Q M N 
R a b b i t V G E GSP P S IQ A M E EN N 
Human V N G S Q N A V E N N 
G . p i g V S G Q L Y V E G S Q N N 
♦ 270 « 2 8 0 290 300 310 320 330 340 
M o u s e TMPNVTFLINEVSYTLNPTDYILPDLVDGMQFCGSGFQGLDIPPPAGPLWILGDVFIRQFYSVFDRGNNQVGLAPAVP. 
R a t M G S A Q K 
R a b b i t I D V G P S A A T F Q S R 
Human V D T G P S A T L F S H R 
G . p i g M L D I G P A T L F V S T E E Q A R 
Fig. 2. Alignment of the deduced amino acid sequences of procathepsin E from mouse, rat, rabbit, human and guinea pig (G. pig). The se-
quence for the murine procathepsin E is given in full. At any given position where no residue is shown, sequence identity with murine proca-
thepsin E exists. (—) indicates the absence of a residue. The positions of the active-site aspartic acid residues, potential N-linked glycosylation 
sites and the Cys residue involved in the formation of the interchain disulflde bridge are indicated by τ , ♦ and v , respectively. 
(i) In addition to the N-linked oligosaccharide at tachment 
site which is present in the enzyme from all of the species 
( ~ Asn 3 4 -X-Thr 3 6 ~ , see Fig. 2), murine cathepsin E con-
tains two additional potential N-glycosylation sites located 
towards the C-terminus (Asn266 and Asn2 7 9) , i.e. murine ca-
thepsin E possesses three sites in total. The glycosylation site 
at Asn266 is present in rat cathepsin E but not in the guinea 
pig sequence; whereas the 'mot i f at Asn2 7 9 is present in the 
guinea pig sequence but not in rat cathepsin E. Thus, rat and 
guinea pig enzymes each have two N-glycosylation sites while 
cathepsin E of human and rabbit origin has only the one 
~ A s n 3 4 - X - T h r 3 6 ~ 'mot i f (Fig. 2). The extent and type of 
N-glycosylation at the additional A s n - X - T h r 'motifs' remains 
to be elucidated [15]. 
(ii) Whereas the unique Cys residue is conserved (as de-
scribed above), the context of the sequence in which it is 
located is the most highly variable of the entire procathepsin 
E molecule (Fig. 2). 
(iii) Modelling of the sequence of the murine cathepsin E on 
the basis of its homology to human cathepsin E [2] suggests 
that, of those residues predicted to make contact with features 
of a substrate or inhibitor bound in the active site [2,20], only 
one residue differs significantly between the mouse and the 
human enzymes. In mouse cathepsin E, the residues which 
contribute to the structural feature of aspartic proteinases 
known as the polyproline loop [21] are ~ P r o 3 0 5 - P r o 3 0 6 -
P r o 3 0 7 ~ (Fig. 2); in human cathepsin E, this sequence is 
~ H i s -P ro -P ro ~ while in the guinea pig, rat and rabbit en-
zymes, the sequence is ~ G i n - P r o - P r o ~ . In order to inves-
tigate whether such changes might influence the nature and 
activity of the cathepsin E molecule significantly, the D N A 
encoding the pro- and mature regions of murine procathepsin 
Table 1 
Kinetic constants for the interactions of chromogenic substrates and inhibitors with recombinant mouse and human cathepsin E 
Substrate or inhibitor Mouse Human Mouse Human Mouse Human Mouse Human 
Ki (nM) Km (mM) fccat (s x) kcJKm (mM-'s-
1 ) 
Substrate 1 
Substrate 2 
Isovaleryl-pepstatin 
Ascaris protein 
50 
60 
65 
160 
130 
110 
70 
125 
2600 
1830 
1070 
780 
<0.1 
1.0 
<0.1 
3.0 
Substrate 1 = Pro-Pro-Thr-Ile-Phe*Nph-Arg-Leu and Substrate 2 = Lys-Pro-Ile-Glu-Phe*Nph-Arg-Leu. (Nph = nitrophenylalanine). 
Substrate 2 was used for the evaluation of the inhibitors. The estimated precision of all values obtained was in the range 10-15%. 
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Fig. 3. SDS-PAGE of samples containing recombinant mouse ca-
thepsin E. Samples (containing ~ 1 mg of protein) were analysed 
under reducing conditions in the presence of 50 mM ß-mercapto-
ethanol (lane 1) or in the absence of reducing agent (lane 2). Stain-
ing was with Coomassie Blue and molecular mass markers (kDa) 
migrated as indicated. 
E was sub-cloned into pET16b to facilitate the production of 
recombinant enzyme. 
3.2. Expression and characterisation of murine procathepsin E 
in E. coli 
The resultant recombinant plasmid was transformed into E. 
coli and induced with 1 mM IPTG. After 3 h, the cells were 
harvested, lysed and the zymogen was extracted with urea and 
re-folded by rapid dilution at pH 9.5 [12,13]. After concen-
tration, the pH of the suspension was adjusted to pH 3.1 and 
the solution was incubated for 1 h at 37°C in order to gen-
erate mature cathepsin E by autoactivation of the recombi-
nant precursor. Following centrifugation, the supernatant was 
neutralised, centrifuged again and aliquots were taken for 
further analyses. 
Analysis by SDS-PAGE under reducing conditions (Fig. 3) 
revealed a single homogeneous protein band of approximately 
~ 4 0 kDa consistent with the molecular mass predicted from 
the deduced amino acid sequence of the mature form of mur-
ine cathepsin E. In contrast, when the electrophoresis was 
performed under non-reducing conditions, the predominant 
band observed migrated at <~80 kDa (Fig. 3), indicating 
that the recombinant enzyme was largely present in the 
form of a disulfide-linked homodimer. A very faint band mi-
grating slightly faster under the non-reducing conditions (Fig. 
3, lane 2) than the single band obtained in the presence of ß-
mercaptoethanol (Fig. 3, lane 1) confimed that only a very 
small proportion of the protein existed as the monomer. Sam-
ples of the purified murine enzyme were subjected to Edman 
degradation but a single unique N-terminal sequence was not 
observed; rather, three distinct overlapping sequences were 
elucidated. All were exactly coincident with the deduced ami-
no acid sequence for the mature murine cathepsin E as pre-
dicted by the cDNA sequence. These N-terminal isoforms 
were present at a ratio of 2:1:0.1, respectively. 
Sequence 1 T-R-L-S-E-S-C-N-V-Y-S-S-V-N-E-P-L-I-N-Y-L~ 
Sequence 2 S-E-S-C-N-V-Y-S-S-V-N-E-P-L-I-N-Y-L~ 
Sequence 3 S-V-N-E-P-L-I-N-Y-L ~ 
The predominant N-termini (sequences 1 and 2) are posi-
tioned identically to the sites located in the human procathep-
sin E sequence at which it has been shown previously [13] that 
autoactivation of the zymogen takes place. This leads to the 
N-terminal microheterogeneity of the resultant mature en-
zyme. It is evident that, in both cases, these activation sites 
are situated immediately upstream of the unique cysteine res-
idue of cathepsin E so that the intermolecular disulfide bond 
is positioned within the mature enzyme (and not in the prop-
art region). 
Two ~ 4 0 kDa molecules are thus connected to generate 
the ~ 8 0 kDa moiety observed by SDS-PAGE under non-
reducing conditions. The importance of this disulfide bond 
for enzymic stability and correct intracellular trafficking of 
cathepsin E has been described previously [12,22]. The third, 
minor sequence detected indicated that a small proportion of 
the zymogen molecules ( < 5%) had undergone processing 
downstream from the cysteine residue. In this case, the result-
ant mature cathepsin E could not be dimeric and, indeed, 
SDS-PAGE did show a minor component (the lowest band 
in lane 2, Fig. 3) with a slightly lower molecular mass under 
non-reducing conditions. The position of this minor activation 
site is similar to one of the processing sites observed upon 
activation of the Cys4Ala mutant form of human cathepsin 
E [12]. Perhaps it should be emphasised that mature cathepsin 
E, irrespective of the species of origin, is longer at its N-ter-
minus by 8 or 11 residues (as a result of the observed N-
terminal microheterogeneity) by comparison with other as-
partic proteinases of fungal or vertebrate species (such as 
pepsin or cathepsin D). One consequence of this is that the 
intermolecular disulfide bond is located in this N-terminal 
'extension' to the archetypal aspartic proteinase molecule; 
the corollary is that the propart released upon autoactivation 
of procathepsin E is necessarily shorter than those generated 
from other aspartic proteinase precursors by an equivalent 
number of residues. In this regard, it is noteworthy that, in 
the propart region of many aspartic proteinase precursors, 
there is a lysine residue in a ~ L y s - T y r ~ 'motif [23] which 
is believed to play a key role in the folding and 3-dimensional 
structure of the zymogens [24]. In the propart region of mouse 
(and other) procathepsin E sequences, this ~ Lys-Tyr ~ 'mo-
tif is not only absent but taking its place are the residues 
which contribute the predominant autoactivation cleavage 
sites. In this context, then, the N-terminus of the minor com-
ponent observed upon autoactivation of murine procathepsin 
E is located almost exactly coincident with the N-terminal 
residues of other aspartic proteinases such as pepsin, gastric-
sin and cathepsin D [2,15]. 
The concentration of purified recombinant murine cathe-
psin E was determined by active site titration using isovaler-
yl-pepstatin as described in Section 2. On this basis, it was 
estimated that the yield of active enzyme was ~ 5 mg/1 of 
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E. coli culture. This is considerably higher (¡= 10- and 3-fold, 
respectively) than those obtained previously for recombinant 
wild-type and mutant (Cys4Ala) human enzymes [12,13] and 
was sufficient to enable crystallisation trials to begin with a 
view to the structural determination of murine cathepsin E. 
3.3. Kinetic parameters for the interaction of substrates and 
inhibitors with recombinant murine cathepsin E 
The ability of the purified recombinant murine enzyme to 
hydrolyse two chromogenic peptide substrates was compared 
with that of human cathepsin E. The kinetic parameters ob-
tained are listed in Table 1. For each substrate, the specificity 
constant derived for the murine enzyme was comparable 
( ~ 2.3-fold higher) to the values derived for the recombinant 
human enzyme and closely similar to those reported previ-
ously for naturally occurring cathepsin E isolated from hu-
man and rat tissues [2,13,14]. Sub-nanomolar K¡ values were 
determined for the interaction of isovaleryl-pepstatin with the 
recombinant mouse and human enzymes (Table 1). A further 
distinguishing feature of cathepsin E is its susceptibility to 
inhibition by a protein (Μτ ~ 1 7 ) from the parasitic worm, 
Ascaris lumbricodes [25]. A K¡ value of 1 n M was determined 
for the interaction of the recombinant murine enzyme (Table 
1) with this protein inhibitor; this value is at most only 2 -3 -
fold different from the value determined for inhibition of hu-
m a n cathepsin E. 
In terms of its interactions with selected substrates and in-
hibitors, murine cathepsin E differs only marginally from its 
human counterpart , and this may be related to differences in 
the sequences of the two proteins. Whether the small changes 
observed are in themselves significant may be discerned from 
a more detailed investigation using mutagenesis together with 
a much larger series of synthetic substrates with systematic 
variation of individual residues [2]. In its other characteristics, 
murine cathepsin E would appear to be virtually indistinguish-
able from its human counterpart and would thus serve as a 
model to facilitate investigations into the human enzyme. To 
this end, the murine c D N A has been used as a probe to isolate 
a genomic clone spanning the entire murine procathepsin E 
gene locus (W. Roth , C. Peters, J. Kay and P. Tatnell, un-
published). This should facilitate attempts to generate a 
'knock-out ' mouse lacking the gene for this important aspartic 
proteinase. 
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